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The present review update the relationship between acetaldehyde (ACE) and parkinsonism
with a specific focus on the role of P450 system and CYP 2E1 isozyme particularly.
We have indicated that ACE is able to enhance the parkinsonism induced in mice by
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a neurotoxin able to damage the nigrostriatal
dopaminergic pathway. Similarly diethyldithiocarbamate, the mainmetabolite of disulfiram,
a drug widely used to control alcoholism, diallylsulfide (DAS) and phenylisothiocyanate
also markedly enhance the toxin-related parkinsonism. All these compounds are
substrate/inhibitors of CYP450 2E1 isozyme. The presence of CYP 2E1 has been detected
in the dopamine (DA) neurons of rodent Substantia Nigra (SN), but a precise function
of the enzyme has not been elucidated yet. By treating CYP 2E1 knockout (KO) mice
with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, the SN induced lesion
was significantly reduced when compared with the lesion observed in wild-type animals.
Several in vivo and in vitro studies led to the conclusion that CYP 2E1 may enhance
the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice by increasing free radical
production inside the dopaminergic neurons. ACE is a good substrate for CYP 2E1
enzyme as the other substrate-inhibitors and by this way may facilitate the susceptibility
of dopaminergic neurons to toxic events. The literature suggests that ethanol and/or
disulfiram may be responsible for toxic parkinsonism in human and it indicates that basal
ganglia are the major targets of disulfiram toxicity. A very recent study reports that there
are a decreased methylation of the CYP 2E1 gene and increased expression of CYP 2E1
mRNA in Parkinson’s disease (PD) patient brains. This study suggests that epigenetic
variants of this cytochrome contribute to the susceptibility, thus confirming multiples lines
of evidence which indicate a link between environmental toxins and PD.
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ALCOHOL CONSUMPTION AND PARKINSON’S DISEASE
A large number of case-control studies analysed the relationship
between Parkinson’s disease (PD) and some environmental fac-
tors (De Lau et al., 2004). Addictive behaviors, such as cigarette
smoking and coffee drinking, showed a protective effect against
PD and parkinsonism. Regarding alcohol consumption, most
studies report either a moderately decreased risk or no change
in risk associated with alcohol intake (Benedetti et al., 2000;
Paganini-Hill, 2001; Hernan et al., 2004; Wirdefeldt et al., 2011;
Campdelacreu, 2012; Noyce et al., 2012; Palacios et al., 2012). In
contrast with these clinical findings, experimental data in rodents
showed that alcohol induces a reduction in the dopamine (DA)
levels in the midbrain, even if contradictory data are present in
literature and an increased oxidative stress in nigral cells (Collins,
2002; Ambhore et al., 2012) and Golgi fragmentation (Tomas
et al., 2012). Likely, alcohol consumption and neurodegenerative
disease (e.g., PD) induce similar effects on intracellular structures
and trafficking (Ambhore et al., 2012). It’s conceivable that some
components of alcoholic beverages (e.g., flavonoids in red wine)
could have a neuroprotective activity (Palacios et al., 2012).
Beer drinkers have a lower risk of PD (Hernan et al., 2003), and
this result can be explained with higher plasma urate levels that
beer induces. Indeed, urate plays a protective role against PD
(Xiang et al., 2008). It has been known that in parkinsonian
patients addiction such as cigarette smoking, drug consump-
tion, alcoholism and compulsive disorders such as gambling,
compulsive shopping, hypersexuality are less common than into
general population (De Lau et al., 2004; Xiang et al., 2008; Noyce
et al., 2012). Data collected in the last decades all over the world
highlight the link between dopaminergic replacement and onset
of addiction behaviors and compulsive disorders in Parkinson’s
patients (Villa et al., 2011). However, alcohol consumption and
a history of alcoholism seem to be related with higher incidence
of impulse control disorders in PD patients receiving dopamin-
ergic replacement (Evans et al., 2005; Wu et al., 2009). Some
endogenous alkaloids, like salsolinol (1-methyl-6,7-dihydroxy-
1,2,3,4-tetrahydroisoquinoline,SAL) and tetrahydropapaveroline
(6,7-dihydroxy-1-(3′ ,4′ -dihydroxybenzyl)-1,2,3,4-tetrahydro-
isoquinoline; THP), whose blood levels are increased by
alcohol, have neurotoxic effects especially in the striatum
and reduce DA content into basal ganglia (Young-Joon and
Hyun-Jung, 2010). THP is detected at a high level in the urine
of parkinsonian patients under L-DOPA therapy (Cashaw,
1993); however, there are very low levels of THP in the
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urine of abstinent alcoholics. Possible implications of THP in
alcohol dependence were inferred from the observation that rats
which normally rejected alcohol, would drink alcohol in excessive
amount following direct delivery of THP (Duncan and Deitrich,
1980). Thus, these substances might contribute to alcohol depen-
dence (Collins, 2004; Hipólito et al., 2012; Deehan et al., 2013).
These factors can be useful to identify PD patients at high risk
of developing impulse control disorders during dopaminergic
replacement.
ACETALDEHYDE AND PARKINSON’S DISEASE
Acetaldehyde (ACE) is the alcohol metabolite responsible for
unpleasant effects such as nausea, vomiting, tachycardia and
hypotension. ACE increases the toxic effect of 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) in striatum (Corsini et al.,
1987; Zuddas et al., 1989a,b, 1992; Vaglini et al., 1996); this
activity has been demonstrated in mice but not in rats (Fornai
et al., 1997). There are no studies in humans that relate ACE to
PD or parkinsonism, most likely because it’s not a substance of
abuse nor a drug nor a pollutant. ACE is further metabolized
to acetic acid with catalysis of Aldehyde dehydrogenase (ALDH);
disulfiram, a blocker of this enzyme, induces ACE accumula-
tion and is used in treatment of alcoholism. Disulfiram can have
a neurotoxic effect; namely, acute intoxication induces unilat-
eral pallidal lesion as described by means of magnetic resonance
evaluation and clinical assessment (De Mari et al., 1993) while
chronic administration can induce Wernicke’s encephalopathy,
with progressive frontal decline and akineto-rigid parkinson-
ism (Charles et al., 2006). Brain MRI revealed symmetrical and
reversible lesions in basal ganglia, but after discontinuation of
disulfiram, clinical recovery was slow and partial. These observa-
tions suggest that basal ganglia are the major targets of disulfiram
neurotoxicity (Laplane et al., 1992). Similar brain lesions are also
observed in “energy deprivation syndromes,” which are toxic,
genetic or nutritional disorders that disrupt enzymes involved in
energy production pathways (Laplane et al., 1992; Charles et al.,
2006). Probably, disulfiram impairs cellular processes involved
in ATP production but the exact mechanism remains unclear.
It’s conceivable that disulfiram toxicity is linked at least in part
to the action of ACE; indeed other aldehydes, such as 3,4-
dihydroxyphenilacetaldehyde (DOPALD), an oxidative metabo-
lite of DA, have been shown to have a neurotoxic activity (Gesi
et al., 2001) and higher levels of these compounds are related with
neurodegenerative diseases (Marchitti et al., 2007) (Figure 1).
ACETALDEHYDE AND EXPERIMENTAL PARKINSONISM
Corsini et al. (1985) unexpectedly found that diethyldithiocar-
bamate (DDC), the main metabolite of disulfiram, markedly
enhanced the MPTP-induced parkinsonism in mice. This effect
was initially interpreted as due to the inhibition of superoxide dis-
mutase leading to an increase in oxidative stress induced by the
toxin. Subsequently, among numerous compounds tested, other
enhancers of MPTP toxicity (ethanol and ACE) were found by
the same authors (Corsini et al., 1987). After this further discov-
ery, this group suggested that these compounds could increase the
potency of the toxin via an inhibition of ALDH within the stria-
tum. The “enhancers,” at the same time, prolonged the striatal
half-life of 1-methyl-4-phenylpyridinium ion (MPP+), the toxic
metabolite of MPTP, (Irwin et al., 1987; Zuddas et al., 1989b)
and this was interpreted as the causative factor of this enhance-
ment. However, in 1996 an article by Vaglini et al. demonstrated
that striatal MPP+ levels do not necessarily correlate with MPTP
toxicity in the same animal species (mouse) and they further on
suggested, as previously reported, that DDC-increased toxicity
was probably due to an independent action on glutamate recep-
tors (Vaglini et al., 1996). However it is likely that the prolonged
storage of MPP+ inside the DA neurons was crucial for its toxic
effects. According to this interpretation, the enzymes, which may
FIGURE 1 | Convergence of metabolic pathway for acetaldehyde and dopamine.
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determine the disposition of MPP+ inside the DA neurons, have
a cardinal role in MPTP toxicity. CYP 2E1 and the CYP 2D family
are the most widely represented isozymes within the DA neurons
(Watts et al., 1998; Riedl et al., 1999) and it is likely that these
two P450 enzymes are responsible for MPP+ clearance. As a mat-
ter of fact, DDC, ethanol and ACE have been discovered to be
specific substrates/inhibitors of CYP 2E1 when they are acutely
administered (Stott et al., 1997) (Figure 2). This specific inhibi-
tion inside the DA neuron may account for the increase in MPP+
striatal half-life, and thus toxicity.
More recently, furthermore, we demonstrated that, similar to
DDC and ACE, CYP 2E1 substrates/inhibitors, such as diallylsul-
fide (DAS) or phenylethylisothiocyanate (PIC) markedly enhance
MPTP toxicity in C57/bl brain, suggesting an involvement of CYP
2E1 in the enhancement of MPTP toxicity. However, because DAS
and PIC are not true CYP 2E1 inhibitors (Nissbrandt et al., 2001),
in order to provide direct evidence for CYP 2E1 involvement, CYP
2E1 knockout (KO) mice and their wild-type counterparts were
challenged with the combined treatment DDC+MPTP (Vaglini
et al., 2004). In that article we consistently showed that an inhi-
bition of the enzyme, as obtained with DDC challenge, failed to
enhance the toxic effect of MPTP in CYP 2E1 KO mice, whereas
the effect was regularly present in wild-type animals. Focusing
on this, we have studied the sensitivity of CYP 2E1 KO mice
to the toxin (Viaggi et al., 2009). The lack of CYP2 E1 did
not increase MPTP toxicity as expected from previous experi-
ments with the inhibitors, and, in fact, the CYP 2E1 KO mice
showed a significant resistance to DA neuronal lesions induced by
the toxin in comparison with their wild-type counterparts. The
reduced sensitivity to MPTP of CYP 2E1 KO mice, but not the
complete insensitivity, may be due to compensatory mechanisms
taking place because of the missing protein. This phenomenon
was observed very clearly by Gonzalez when his team gener-
ated these mice in order to study acetaminophen-induced liver
toxicity (Lee et al., 1996). This drug causes liver and kidney necro-
sis when it is metabolized to an alkylating intermediate by the
P450 system, and more specifically by CYP 2E1 (Jollow et al.,
1973; Mitchell et al., 1973; Gonzalez, 2007). CYP 2E1 KO mice
were generated to strengthen the specific role of CYP 2E1 dur-
ing acetaminophen toxicity (Lee et al., 1996). The CYP 2E1 KO
mice were less sensitive to the hepatotoxicity of the drug but
they were not completely unaffected. A compensatory isozyme
of the P450, probably CYP2D6, was substituted, thus producing
the same—though reduced—toxic effect. Very recently we gener-
ated mesencephalic cell cultures from CYP 2E1 KO and wild-type
embryos to investigate MPP+ toxicity and its cell distribution. In
this model we demonstrated that a trace amount of MPP+ accu-
mulates inside the neurons from KO mesencephalic cultures in
a quantity double than that from wild-type embryos, although
the KO cultures are less lesioned by the toxin (manuscript in
preparation). We then suggested, once inside the cell (or stri-
atal synaptic terminal), MPP+ entered preferentially into vesicles
where its storage represented a sort of protection with respect to
other toxic sites such as mitochondria.
In conclusion CYP 2E1 may facilitate the transfer of MPP+ to
mitochondria for further metabolism. Alternatively and indepen-
dently from MPP+ disposition, CYP 2E1 produces toxic reactive
intermediates from endogenous or exogenous substrates which in
turn impair neuronal viability.
THE P450 SYSTEM IN PD
In 1985, Barbeau et al. elegantly presented evidence for an asso-
ciation of a CYP 2D6 defect with PD (Barbeau et al., 1985).
Indeed, they postulated that subjects with a reduced CYP 2D6
enzyme (poor metabolizers) are vulnerable for PD because of the
impaired capacity of liver to detoxify those neurotoxins which are
harmful for DA neurons. It is worth noting that further stud-
ies have actually indicated CYP 2D6 as the major detoxifying
liver enzyme for the PD-inducing neurotoxin, MPTP (Coleman
et al., 1996; Gilham et al., 1997). After this pioneering report,
however, many conflicting results were obtained in phenotypic
and genotypic CYP 2D6 studies, which have been outlined in a
comprehensive review by Riedl et al. (1998).
Several enzymes involved in the metabolism of endogenous
compounds and xenobiotics have been studied in relation to
PD. However, CYP450 in particular drew attention, due to its
ability to defend the body against xenobiotic aggression. In par-
ticular, six P450 enzymes have been examined with respect to
PD: CYP 1A1 (Kurth and Kurth, 1993; Bennet et al., 1994;
Takakubo et al., 1996), CYP 2C9 (Ferrari et al., 1990; Peeters
FIGURE 2 | Role of CYP 2E1 in metabolizing ethanol and acetaldehyde.
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et al., 1994), CYP 2C19 (Gudjonsson et al., 1990; Tsuneoka et al.,
1996), CYP 1A2, CYP 2E1 (Factor et al., 1989; Steventon et al.,
1989), and CYP 2D6 (Riedl et al., 1998). Since the first enthusi-
astic claim, more than 50 reports have debated the role of CYP
2D6 in the pathogenesis of PD. Subsequent phenotypic stud-
ies have failed to support a link between this isozyme and PD.
Similarly, the most extensive genetic studies initially confirmed
this link, but a critical analysis of the recent studies from differ-
ent groups again failed to draw any definitive conclusion (Riedl
et al., 1998). Indeed, with respect to CYP 2D6, no laboratories
have succeeded in replicating the initial report of Smith et al.
(1992), according to which the frequency of poor metabolizers
significantly increased in a PD population. Subsequent reports
have been conflicting, although some groups have claimed dif-
ferences in the allelic frequency of CYP 2D6∗4 and other CYP
2D6 allelic variants in PD. Two recent meta-analyses failed to find
an increased frequency of poor metabolizers among PD patients
(Christensen et al., 1998; Rostami-Hodjegan et al., 1998). On the
contrary, an earlier meta-analysis suggested a weak association,
but this included fewer studies (McCann et al., 1997). As a result
of their inability to observe any association, other authors per-
formed sub-group analyses, thus suggesting a possible link with
“young onset PD” (Agundez et al., 1995) or PD with prominent
tremor (Akhmedova et al., 1995). Unfortunately, these findings
have not been replicated, either (Sandy et al., 1996). Although
most studies have been negative, there are some critical issues
that have been addressed by Le Couteur and McCann (1998) in
connection with this problem. First, it is unlikely, on the basis
of current studies, to completely refute the involvement of CYP
2D6, as, in order to have a definitive study of a statistical power,
one would need almost 3000 subjects to exclude a 50% increase
in the frequency of poor metabolizers among PD patients. The
second issue is that studies should consider only patients who
have had neurotoxin exposure. If CYP 2D6 polymorphism influ-
ences vulnerability to PD by affecting the metabolism of an
environmental neurotoxin, then studies should include only those
subjects who have undergone this kind of neurotoxin exposure.
The authors concluded that this stratification for toxin exposure
is necessary in order to rule out the role of CYP 2D6 in the
pathogenesis of PD.
This last concept of an environmental toxin and CYP 2D6, as
its metabolizing enzyme, opens an old issue regarding the toxic
hypothesis of PD, which originated from the incidental discov-
ery of MPTP as a widespread impurity (Langston et al., 1983).
Indeed, MPTP is metabolized by some P450 enzymes and by CYP
2D6 in particular (Coleman et al., 1996; Gilham et al., 1997) and
has recently been discovered to be a synthetic impurity of het-
erocyclic drugs (Kramer et al., 1998). In this study, the authors
assessed the risk of administering MPTP orally and reported
that compounds containing less than 5 p.p.m. of MPTP do not
involve any neurotoxicological health risk. They concluded sur-
prisingly that it may be assumed thatMPTP is also present as a yet
undiscovered minor impurity in various existing drugs (Kramer
et al., 1998). If this was true, MPTP or one of its analogues
would represent the toxin probably responsible not for idiopathic
PD, but for a specific subgroup of parkinsonism. In this case,
CYP 2D6-related metabolism would be of extreme importance
and phenotypic and genotypic studies should be carried out on
different and selected types of subjects.
P450 IN EXPERIMENTAL PARKINSONISM
In general, MPP+ metabolism, unlike MPTP, has been poorly
investigated. Johannessen et al. (1985) postulated that MPP+
may be transformed into free radical species, and other authors
provided evidence for CYP 2D isoform involvement (Fonne-
Pfister and Meyer, 1988; Jolivalt et al., 1995). It is interesting to
note that CYP 2E1 is associated with the metabolism of several
small planar molecules, such as nitrosoamines, benzene, alco-
hol and 3-hydroxypiridine (Parkinson, 1996), and is present in
a functional form because its levels can be induced by prior
treatment with isoniazid (Park et al., 1993). CYP 2E1 therefore
may represent, in this particular case, a detoxification pathway of
MPP+, whose inhibition by DDC leads to an increased toxicity.
A similar conclusion can be drawn for CYP 2D isozymes. CYP
2D6, the isoform present in humans and monkeys, metabolizes
MPTP and MPP+ probably to harmless compounds (Fonne-
Pfister and Meyer, 1988; Jolivalt et al., 1995; Coleman et al.,
1996; Gilham et al., 1997). Therefore, “CYP 2D6 poor metabo-
lizers,” or the drugs that inhibit this isoenzyme, may represent
susceptible factors favoring the neurotoxicity induced by MPTP
(Barbeau et al., 1985; Lane, 1998). It is worth noting that MPP+
binding sites, as described by Del Zompo et al. (1986), may
partly correspond in the mouse brain to the substrate recog-
nition sites of CYP 2D isozymes. This MPP+ binding, indeed,
is displaced potently by debrisoquine and its analogues, which
are good substrates for the P450 system (Del Zompo et al.,
1990). MPP+ binding has also been studied in post-mortem
brain of PD patients and, among the several brain areas ana-
lyzed, only the Substantia Nigra (SN) showed a reduction in
this binding in comparison with age-matched controls (Corsini
et al., 1988). This reduction may be interpreted as a result
of CYP 2D6 loss in the SN following DA neuron degenera-
tion, a finding which is similar to that observed by Riedl et al.
(1999) in the rat brain after 6-OHDA lesion of DA neurons.
Furthermore, CYP 2D isoforms not only metabolize the neuro-
toxins MPTP and/or MPP+, but also markedly participate in the
metabolism of methamphetamine and its analogues (Lin et al.,
1995). Actually, similar conclusions must be drawn for these toxic
compounds which are widely abused by humans. The role of
CYP 2D6-mediated metabolism of amphetamines must be con-
sidered not only for the hepatic enzyme, but also for the one
present in DA neurons. At present, it is difficult to suggest the
effective physiological role of this enzyme in the DA neuron. It is
likely that it behaves like a guard against endogenous or exoge-
nous harmful intruders (false transmitters) which may affect DA
metabolism. The concept of a “false transmitter” implies that
endogenous chemicals may be handled within the neurons like
the natural transmitter, thereby influencing the intraneuronal dis-
position and release of the natural transmitter (Thoenen, 1969).
Among the various false transmitters which affect DA neurons,
tryptamine is one of the most widely studied (Baumgarten and
Zimmermann, 1992). Tryptamine is an endogenous substrate
of CYP 2D6 (Martinez et al., 1997) and its involvement in PD
and in schizophrenia as well has been evaluated since the 60’s
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(Brune and Himwhich, 1962; Keuhl et al., 1968; Herkert and
Keup, 1969; Smith and Kellow, 1969).
CYTOCHROME P450 2E1
The highest concentration of the enzyme CYP 2E1 is in the
liver where it is the main P450 enzyme for ethanol metabolism
(Thomas et al., 1987; de Waziers et al., 1990; Correa et al., 2009).
However, it has been found in many extrahepatic organs, for
example in kidney and lung. CYP 2E1 is specifically implicated
in the metabolism of several compounds including toxicants
and low molecular weight procarcinogens (Koop, 1992). Among
the many endogenous substrates of the enzyme that have been
identified (Ronis et al., 1996; Lieber, 1997; Ingelman-Sundberg,
2004), are ketones (e.g., acetone) and fatty acids such as arachi-
donic acid. The exogenous compounds metabolized by CYP 2E1
comprise a wide variety of xenobiotics (e.g., acetaminophen, ani-
line, paracetamol, N-nitrosodimetylamine, and chlorzoxazone,
with the latter two often used as enzymatic probes), alcohols
(e.g., ethanol, methanol), ACE, aromatic hydrocarbons such as
benzene and toluene, halogenated hydrocarbons (e.g., carbon
tetrachloride) and finally anesthetics including enflurane, isoflu-
rane, and halothane. Its active site pocket is relatively small and
hydrophobic, creating a suitable environment for small non-polar
molecules. Due to its existence predominantly as high spin form,
CYP 2E1 also is important in oxygen reduction and generation
of reactive oxyradicals, potent initiators of membrane lipid per-
oxidation (Ekstrom and Ingelman-Sundberg, 1989; Persson et al.,
1990).
Several isoenzymes of P450 have been identified in the CNS
of several animal species, including man (Kalow, 1992; Warner
et al., 1993). Altough the activities of the different cytocromes in
the brain are very low as compared to in the liver, CYP 2E1 has
been detected by immunohistochemical techniques in the DA-
containing areas, the striatum and the SN (Anandatheerthavarada
et al., 1993a; Gonzalez and Kimura, 1999). As in the liver, CYP 2E1
in brain is inducible by, e.g., ethanol, isoniazid or nicotine admin-
istration (Anandatheerthavarada et al., 1993b; Sohda et al., 1993;
Gonzalez and Kimura, 1999). Also, induction of this enzyme
during ischemic injury was shown in hippocampal and cortex
astrocytes of rat and gerbil in vivo (Tindberg et al., 1996; Watts
et al., 1998) showed that inducible CYP 2E1 existed in the same
compartment as tyrosine hydroxylase in the rat SN but could not
detect the enzyme in nigral glia cells. In addition, localization
of the enzyme in monkey brain, as well as prenatal and adult
human brain was confirmed (Brzezinski et al., 1999; Upadhya
et al., 2000; Joshi and Tyndale, 2006). The active form of CYP 2E1
has been found in ER (microsomes), in the Golgi apparatus and
in the plasmamembrane of rat hepatocytes (Wu and Cederbaum,
1992; Loeper et al., 1993; Neve et al., 1996). It is possible that in
the CNS, the active form of this enzyme is localized in the same
membrane compartments as its hepatic variety.
There is evidence that interindividual variability in the expres-
sion and functional activity of this cytochrome may be consid-
erable. Genetic polymorphisms in CYP 2E1 were identified and
linked to altered susceptibility to hepatic cirrhosis induced by
ethanol and esophageal and other cancers in some epidemiologi-
cal studies. Therefore, it is important to evaluate how such poly-
morphisms affect CYP 2E1 function and whether it is possible
to construct a population distribution of CYP 2E1 activity based
upon the known effects of these polymorphisms and their fre-
quency in the population (Itoga et al., 2002; Danko and Chaschin,
2005).
Recently, considering these findings on the enzymatic prop-
erties and genetic characteristics of CYP 2E1 and the fact that
the enzyme is found in the SN, preliminary data demonstrated
a possible association between CYP 2E1 polymorphisms and PD
(Shahabi et al., 2009).
More recently Kaut et al. (2012) found decreased methylation
of the cytochrome CYP 2E1 gene and increased expression of CYP
2E1 messenger RNA in PD patients’ brains, suggesting that epige-
netic variants of this cytochrome contribute to PD susceptibility.
Alterations of gene methylation patterns may form an interface
between genetic and environmental susceptibility, carrying for-
ward long lasting changes which may have been acquired even
in preceding generations (Feinberg, 2007; Suzuki and Bird, 2008;
Urdinguio et al., 2009).
Summarizing the above mentioned paragraphs the use of
ACE, or other CYP 2E1 substrates/inhibitors as well, revealed the
role of a specific P450 enzyme in experimental parkinsonism as
obtained in the MPTP mouse model. Similarly clinical studies
in PD led to the conclusion that environmental factors, such as
several xenobiotics, contribute to the development of the disease.
Among the relevant toxic environmental chemicals, pesticides
and volatile solvents are the most suspected ones which are all
substrates of CYP 2E1. It is likely that the oxidative stress induced
by these substrates, including ethanol and its main metabolite
ACE, may trigger a chronic impairment of DA neurons leading
to degeneration. CYP 2E1 epigenetic alterations may facilitate the
degenerative process through the metabolism of such xenobiotics
and represent the genetic susceptibility to the disease. CYP 2E1
might be just the tip of the iceberg of epigenetic alterations to be
identified in apparently sporadic neurodegenerative disorders.
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